2024-519499-22-00招募中1 期
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals Inc.3 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2025年6月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 31
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Alnylam Clinical Trial Information Line
Scientific
Alnylam Pharmaceuticals Inc.
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
不适用
Breath Test for Patients with Acute Liver Disease for early Detection of the Need for Transplant or Recovery - Breath Test for Patients with Acute Liver DiseaseThe study will look at the liver metabolic function in patients with acute liver failure.EUCTR2009-011926-32-GBExalenz Bioscience Ltd112
尚未招募
不适用
HepaFatTM Scan for the non-invasive measurement of liver fat using magnetic resonance imagingon-alcoholic fatty liver disease (NAFLD)Hepatic steatosisNon-alcoholic fatty liver disease (NAFLD)Metabolic and Endocrine - Other metabolic disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12612000025831Resonance Health Analysis Services Limited90
已完成
不适用
RAIB-TACE for the Patients with Hepatocellular Carcinoma beyond Up-to 7 Criteria (RAIB-TACE for the Patients with Hepatocellular Carcinoma beyond Up-to 7 Criteria)Hepatocellular CarcinomajRCTs03120033419
进行中（未招募）
1 期
A Study of LY2157299 in Patients With Liver CancerCarcinoma, hepatocellularMedDRA version: 20.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864EUCTR2010-022338-10-DEEli Lilly and Company204
已完成
不适用
AFP – L3% and DCP as screening marker for a hepatocellular carcinoma in patients with cirrhosis of the liverC22.0K74.6Liver cell carcinomaOther and unspecified cirrhosis of liverDRKS00000811KL Freiburg, Med. Klinik II400